* Gritstone bio Inc GRTS.OQ GRTS.O is expected to show a
fall
in quarterly revenue when it reports results on August 2
(estimated).
* The Emeryville California-based company is expected to
report
a 54.3% decrease in revenue to $2.5 million from $5.47 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Gritstone bio Inc
is for
a loss of 35 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Gritstone
bio Inc
is $7, above its last closing price of $1.97.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.33 -0.33 -0.30 Beat 10.3
Dec. 31 2023 -0.31 -0.34 -0.30 Beat 12.8
Sep. 30 2022 -0.37 -0.40 -0.35 Beat 12.1
Jun. 30 2022 -0.39 -0.40 -0.34 Beat 14.1
Mar. -0.35 -0.37 -0.34 Beat 7.5
31 2022
Dec. 31 2021 -0.34 -0.38 -0.37 Beat 3.3
Sep. 30 2021 -0.49 -0.52 -0.36 Beat 30.6
Jun. 30 2021 -0.58 -0.58 -0.33 Beat 42.8
This summary was machine generated August 1 at 02:07 GMT. All
figures in US dollars unless otherwise stated